Published in Mental Health Law Weekly, February 24th, 2007
Teva filed the complaints in the United States District Courts of New Jersey, Delaware, Southern District New York, and Maryland for infringement of its U.S. Patents Nos. 6,600,073 (expiring June 2020), 6,500,987 (expiring November 2019), 6,495,721 (expiring May 2020) and 6,897,340 (expiring April 2023), covering processes of making sertraline hydrochloride.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly